TheiaNova, a University of Auckland spinout, reported early results from a first-in-human trial of its keratoconus eye drop. The Australian study included 20 patients. No safety concerns have arisen, and the drop was well tolerated.
Trial design
The six-month trial tested two doses of the patented formula. Ten eyes received each dose. Preliminary efficacy data are due in December.
Company and research base
The treatment was developed by Emeritus Professor Colin Green and Professor Trevor Sherwin. They work in the University of Auckland's Department of Ophthalmology. Dr Carissa Fonseca serves as TheiaNova's CEO.
How the drop works
The formula combines human growth factor TGF-β3 with an ultra-low dose of dexamethasone. It aims to stimulate corneal cells to produce new collagen. That may restore structural stability to the cornea.
TheiaNova is planning a phase 1b/2a study focused on safety and efficacy endpoints. It is also considering a 12-month follow-up with trial patients. The company is raising capital with Flying Kiwi Angels as lead investor.
Read more: nbr.co.nz